Izana Bioscience Initiates Namilumab Phase II Proof-of-Concept Clinical Study in Ankylosing…
Izana Bioscience announced the initiation of a phase II proof-of-concept clinical study of namilumab in ankylosing spondylitis, a debilitating arthritic disease of the spine that…
Read More...
Read More...